SEC Form 4 · accession 0001209191-18-039670
Kezar Life Sciences, Inc. · KZR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Franklin Fowler
Officer — CEO · Director
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645666
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $5.91 | Jun 25, 2018 | A | 88,967 | A | Jun 25, 2018 | Apr 15, 2028 | Common Stock | 88,967 | 88,967 | D |
Explanation of responses
- F1100% of the shares subject to the option vested and became exercisable upon the closing of the initial public offering in accordance with its terms.